154 related articles for article (PubMed ID: 17419264)
1. Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin.
Li S; Niu Z; Tian H; Zhang B; Wang F; Yi LH; Yu J
Hepatogastroenterology; 2007; 54(73):218-23. PubMed ID: 17419264
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.
Asnacios A; Fartoux L; Romano O; Tesmoingt C; Louafi S S; Mansoubakht T; Artru P; Poynard T; Rosmorduc O; Hebbar M; Taieb J
Cancer; 2008 Jun; 112(12):2733-9. PubMed ID: 18412149
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.
Zhu AX; Blaszkowsky LS; Ryan DP; Clark JW; Muzikansky A; Horgan K; Sheehan S; Hale KE; Enzinger PC; Bhargava P; Stuart K
J Clin Oncol; 2006 Apr; 24(12):1898-903. PubMed ID: 16622265
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.
Yang TS; Lin YC; Chen JS; Wang HM; Wang CH
Cancer; 2000 Aug; 89(4):750-6. PubMed ID: 10951336
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients.
Shan YS; Lin PW
Hepatogastroenterology; 2007; 54(79):2141-5. PubMed ID: 18251177
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
Louafi S; Boige V; Ducreux M; Bonyhay L; Mansourbakht T; de Baere T; Asnacios A; Hannoun L; Poynard T; Taïeb J
Cancer; 2007 Apr; 109(7):1384-90. PubMed ID: 17330837
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.
Williet N; Dubreuil O; Boussaha T; Trouilloud I; Landi B; Housset M; Botti M; Rougier P; Belghiti J; Taieb J
World J Gastroenterol; 2011 May; 17(17):2255-8. PubMed ID: 21633538
[TBL] [Abstract][Full Text] [Related]
9. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J
Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.
Ch'ang HJ; Wang CC; Cheng AL; Hsu C; Lu YS; Chang MC; Lin JT; Wang HP; Shiah HS; Liu TW; Chang JY; Whang-Peng J; Chen LT
J Gastroenterol Hepatol; 2006 May; 21(5):874-9. PubMed ID: 16704539
[TBL] [Abstract][Full Text] [Related]
11. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.
Patt YZ; Murad W; Fekrazad MH; Baron AD; Bansal P; Boumber Y; Steinberg K; Lee SJ; Bedrick E; Du R; Lee FC
Cancer Med; 2017 Sep; 6(9):2042-2051. PubMed ID: 28801995
[TBL] [Abstract][Full Text] [Related]
12. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.
Mir O; Coriat R; Boudou-Rouquette P; Ropert S; Durand JP; Cessot A; Mallet V; Sogni P; Chaussade S; Pol S; Goldwasser F
Med Oncol; 2012 Dec; 29(4):2793-9. PubMed ID: 22427209
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine.
Ulrich-Pur H; Kornek GV; Fiebiger W; Schüll B; Raderer M; Scheithauer W
Oncology; 2001; 60(4):313-5. PubMed ID: 11408798
[TBL] [Abstract][Full Text] [Related]
16. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
17. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.
Bidoli P; Stani SC; Mariani L; De Candis D; Cortinovis D; Aglione S; Zilembo N; Toffolatti L; Formisano B; Bajetta E
Lung Cancer; 2004 Feb; 43(2):203-8. PubMed ID: 14739041
[TBL] [Abstract][Full Text] [Related]
19. A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.
Starling N; Hawkes EA; Chau I; Watkins D; Thomas J; Webb J; Brown G; Thomas K; Barbachano Y; Oates J; Cunningham D
Ann Oncol; 2012 Apr; 23(4):942-7. PubMed ID: 21750117
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data.
Airoldi M; Cattel L; Passera R; Pedani F; Delprino L; Micari C
Am J Clin Oncol; 2006 Oct; 29(5):490-4. PubMed ID: 17023785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
